Current and Emerging Prognostic Biomarkers in Endometrial Cancer
Endometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority present with adverse clinico-pathological character...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.890908/full |
| _version_ | 1818061067183456256 |
|---|---|
| author | Kelechi Njoku Kelechi Njoku Kelechi Njoku Chloe E. Barr Chloe E. Barr Emma J. Crosbie Emma J. Crosbie |
| author_facet | Kelechi Njoku Kelechi Njoku Kelechi Njoku Chloe E. Barr Chloe E. Barr Emma J. Crosbie Emma J. Crosbie |
| author_sort | Kelechi Njoku |
| collection | DOAJ |
| description | Endometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority present with adverse clinico-pathological characteristics that herald a poor prognosis. Prognostic biomarkers that reliably select those at greatest risk of disease recurrence and death can guide management strategies to ensure that patients receive appropriate evidence-based and personalised care. The Cancer Genome Atlas substantially advanced our understanding of the molecular diversity of endometrial cancer and informed the development of simplified, pragmatic and cost-effective classifiers with prognostic implications and potential for clinical translation. Several blood-based biomarkers including proteins, metabolites, circulating tumour cells, circulating tumour DNA and inflammatory parameters have also shown promise for endometrial cancer risk assessment. This review provides an update on the established and emerging prognostic biomarkers in endometrial cancer. |
| first_indexed | 2024-12-10T13:42:25Z |
| format | Article |
| id | doaj.art-608023241c154dea80935ab37b8657fc |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T13:42:25Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-608023241c154dea80935ab37b8657fc2022-12-22T01:46:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.890908890908Current and Emerging Prognostic Biomarkers in Endometrial CancerKelechi Njoku0Kelechi Njoku1Kelechi Njoku2Chloe E. Barr3Chloe E. Barr4Emma J. Crosbie5Emma J. Crosbie6Division of Cancer Sciences, University of Manchester, Manchester, United KingdomStoller Biomarker Discovery Centre, University of Manchester, Manchester, United KingdomDepartment of Obstetrics and Gynaecology, St Mary’s Hospital, Manchester, University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United KingdomDivision of Cancer Sciences, University of Manchester, Manchester, United KingdomDepartment of Obstetrics and Gynaecology, St Mary’s Hospital, Manchester, University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United KingdomDivision of Cancer Sciences, University of Manchester, Manchester, United KingdomDepartment of Obstetrics and Gynaecology, St Mary’s Hospital, Manchester, University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United KingdomEndometrial cancer is the most common gynaecological malignancy in high income countries and its incidence is rising. Whilst most women with endometrial cancer are diagnosed with highly curable disease and have good outcomes, a significant minority present with adverse clinico-pathological characteristics that herald a poor prognosis. Prognostic biomarkers that reliably select those at greatest risk of disease recurrence and death can guide management strategies to ensure that patients receive appropriate evidence-based and personalised care. The Cancer Genome Atlas substantially advanced our understanding of the molecular diversity of endometrial cancer and informed the development of simplified, pragmatic and cost-effective classifiers with prognostic implications and potential for clinical translation. Several blood-based biomarkers including proteins, metabolites, circulating tumour cells, circulating tumour DNA and inflammatory parameters have also shown promise for endometrial cancer risk assessment. This review provides an update on the established and emerging prognostic biomarkers in endometrial cancer.https://www.frontiersin.org/articles/10.3389/fonc.2022.890908/fullendometrial cancerprognosisbiomarkersrisk stratificationtreatment |
| spellingShingle | Kelechi Njoku Kelechi Njoku Kelechi Njoku Chloe E. Barr Chloe E. Barr Emma J. Crosbie Emma J. Crosbie Current and Emerging Prognostic Biomarkers in Endometrial Cancer Frontiers in Oncology endometrial cancer prognosis biomarkers risk stratification treatment |
| title | Current and Emerging Prognostic Biomarkers in Endometrial Cancer |
| title_full | Current and Emerging Prognostic Biomarkers in Endometrial Cancer |
| title_fullStr | Current and Emerging Prognostic Biomarkers in Endometrial Cancer |
| title_full_unstemmed | Current and Emerging Prognostic Biomarkers in Endometrial Cancer |
| title_short | Current and Emerging Prognostic Biomarkers in Endometrial Cancer |
| title_sort | current and emerging prognostic biomarkers in endometrial cancer |
| topic | endometrial cancer prognosis biomarkers risk stratification treatment |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.890908/full |
| work_keys_str_mv | AT kelechinjoku currentandemergingprognosticbiomarkersinendometrialcancer AT kelechinjoku currentandemergingprognosticbiomarkersinendometrialcancer AT kelechinjoku currentandemergingprognosticbiomarkersinendometrialcancer AT chloeebarr currentandemergingprognosticbiomarkersinendometrialcancer AT chloeebarr currentandemergingprognosticbiomarkersinendometrialcancer AT emmajcrosbie currentandemergingprognosticbiomarkersinendometrialcancer AT emmajcrosbie currentandemergingprognosticbiomarkersinendometrialcancer |